While I realize that realistic101�s & onyxmole's
obvious hatred for all that is Onyx is painfully obvious,
these individuals have given pretty reliable info in
the past. If we go back to some of their earlier
posts about people and events at Onyx, they have been
right on (but definitely not about stock prices). And
unfortunately, I must say realistic101 is apparently on the mark
Yes, David Kirn (VP Clinical Research) has given
notice or will soon.
Yes, Amy Waterhouse (regulatory
affairs) has given notice.
Yes, Clara Heise (Scientist,
animal testing) has given notice.
And while I can�t
confirm the Marilyn Wortzman conjecture, I too have heard
that Norman Hardman is being forced out (after less
than one year on the job.)
(Don�t believe me?
Simply call the company and ask.)
All of these
leavings raise some serious questions. Such as, how does
Onyx expect to begin Phase III trials without a VP of
Clinical Research and the head of Regulatory affairs, let
alone a COO. Am I the only one on this board that is
concerned that there has been no news concerning the start
of Phase III? Doesn�t Onyx now have the money to
begin the trial through the deal with WLA? Doesn�t Onyx
have FDA approval as the press release stated? So what
is the problem? I would think Onyx would want to
start these trials, oh I don�t know, maybe NOW. I
realize there are many obstacles to beginning these
trials, but it seems many of them have been cleared. And
didn�t one press release state they would start last
November. Is there some problem others would like to shed
some light on? I know there were rumors of virus
production problems on this message board a while back, are
we now seeing the effects of these
I would also think that WLA can�t be too pleased
with all these departures. Obviously, they partnered
with Onyx to get 015, but that deal also included two
new viruses. How can Onyx have any directional
leadership to create these new viruses with all these people
leaving? And more realistically, forget any new viruses,
WLA probably wanted viruses that had already been in
production (such as that RB virus, see press release Sept3,
1998). But how can Onyx test these viruses when the head
of animal testing is leaving? And why haven�t we
heard anything about the RB virus?
Hey, I am not
an Onyx hater. I think the science that has been
there has been top-notch. But I am concerned about
these negative events. Where is Phase III? Where is
that new RB virus? And why does it seem like half the
company always has one foot out the door? And why does
the company never inform investors of these
Any answers out there?
There are major conflicting forces at work on
these issues. First off, I understand the hard feelings
of going from the inside to the outside, 101, Mole,
et al, so my reactions to your comments is aimed at
the lack of influence these matters have on share
Secondly, does everyone think that WLA is a bunch of
idiots? They have excellent access to management at ONYX
and are certainly aware of the larger issues of any
danger to the clinical trials for ONYX-15. They don't
appear to be too concerned at this point, I am certain
that we will hear should their level of concern be
My point is simply that Onxy (assuming the success
ofO-15) will probably prosper (and us along with it),
these sorts of personality problems are not unusual,
read some of the other boards (try Health
Let's try to stick to matters that are likely to affect
shareholder value, that is why we are here, isn't it?
As a relatively new ONXX investor, my investment
is based principally upon two facts: (1) the
company's lead product, 015, has shown positive clinical
results in H&N cancer and (2) the company has forged a
major partnership with a global pharma partner (WLA)
which further endorses its potential commercial value.
While by no means a formula for success, this is
exactly what a fledgling biotech company must do to reach
the next level of development. Skeptics and outright
ONXX haters should tip their hats for such efforts.
Nonetheless, if such negative comments are true (and the
credibility of tone suggests they may be), it does not change
the fact that, barring safety issues or poor
efficacy, the continued development of 015 will bring
significant value to ONXX shareholders from present price
Don't get me wrong - management is a
critical component to this equation. And if true,
would suggest that shareholders find comfort knowing
that ONXX has passed the 015 "baton" to WLA at the
beginning of the Phase III lap. But there are recent
examples of how key defections have only temporarily
impacted the valuation of a company. I point specifically
to the resignation of Coulter Pharmaceutiucls'
(NASDAQ:CLTR) Chief Medical Officer, George Tidmarsh, who
resigned in Nov. 99 in the wake of the Bexxar BLA delay.
Quoting from the new report:
"Some analysts said
the timing of Tidmarsh's announcement was odd, given
that the company is rushing to get the Bexxar
application approved before a similar drug from rival
Pharmaceuticals Corp. Tidmarsh supervised the clinical trials
upon which Coulter based its application. ``It's a bad
sign,'' said Craig Parker, a Donaldson Lufkin & Jenrette
Granted, Tidmarsh didn't leave
the company (transitioned to a business development
role), but the story still crushed the stock price (at
the time $14 per share). Now that the BLA is poised
for resubmission (along with further supportive
data), CLTR shares are trading in the high $20's again.
As for 015 manufacturing issues, let's hope WLA has
done sufficient due diligence to rule out the
possibility of product supply or QA control becoming a
Nonetheless, it would seem that these
critizisms are overblown. But I must also admit that I truly
enjoyed the sarcastic humor of 101.
Onyxnewbie, you suggested calling the company and "just ask"
to confirm such possible departures. Based on this
suggestion, I assume that you have already called the
company. Who did you speak to? I don't know any other
company that would divulge such confidential information.
As for a press release stating when the phase III
trial would start, I quote from the recent press
release on the ONXX-WLA agreement:
Warner-Lambert are preparing to initiate a pivotal Phase III
clinical trial of ONYX-015 in the fourth quarter of 1999
or early in 2000 that combines the virus with
chemotherapy as a treatment for patients with recurrent head
and neck cancer."
Onyxmole has been around for a while. Onyxfriend,
Onyxnewbie and Onyxwaytoolong (such clever names) seem to be
very recent arrivals. My last message: integrity
should better read credibility or "motive". Do people
really think they can influence a few small investors
holding enough shares to get a significant amount of
price movement by their postings? Get real. Especially
with such a small play as Onyx. I'm gonna have to go
look at the Lucent message board to see if there are
any Lucentlong, Lucentmole, Lucentnewbie, etc.,
posting there. Maybe we CAN make a difference, eh?
Let me pose this question: Why are there several
inviduals posting to this board who use the name onyx in
their name? Do these same people post elsewhere with
the "onyx" monniker? If so, it would seem silly. It
suggests to me that they have selected to post under these
pseudonyms on this board for a reason, and I for one, will
question their integrity. Make your own decisions about
Onyx as an investment or trading play. -AC (or
AOnyxPhobiaCat as far as this board is concerned)
the ONXX bulls pick up the freag'n phone and call
to ask whether these two individuals are
Doesn't this make sense?
I think it is stupid to get
angry at people for posting anti-ONXX news? Lets for
ONE second assume that these two guys are telling the
truth. Don't you think this is embarrassing for the
company? Wouldn't you wanna know ahead of time so that you
don't wake up in the morning and your stock is at 2
dollars? I never understood why people get married to a
stock!! The science might be great but a bad management
team will kill you.
Stop bitching at the people
that give opposing views to your "beloved" company.
You are not investors if you don't take into account
the good and the bad in a company. You are just
sheep, following what the big guys tell you. And I have
a surprise for all of you:
There are good things
and bad things about EVERY comopany.
On the other
hand who knows, maybe the departure of these two
people is good for the company.